IQVIA Holdings Inc.

IQV · NYSE · USD

The debate turns on whether IQVIA's rising trial awards and biotech funding mark a durable upturn in outsourcing demand or a cyclical rebound that slower pharma decisions will cap.

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Clinical bookings momentum

    The bull case is that demand for outsourced clinical trials has turned and IQVIA is winning a larger share of awards from both large drugmakers and biotechs.

  • AI agents in client workflows

    A second support is IQVIA's proprietary health data and AI agents, which management says win contracts outright and are used inside most of the largest drugmakers.

  • Emerging biotech funding

    Biotech funding has rebounded and IQVIA says it wins more of that segment's trial work than any competitor, so a funding recovery feeds straight into bookings.

  • Cash conversion funds buybacks

    Because the business converts nearly all of its adjusted profit into cash, it can fund share repurchases and small acquisitions without issuing new equity.

Bear case

  • Lumpy quarterly trial awards

    The bear case is that quarterly awards swing with a handful of trial decisions and pass-through billing, so reported book-to-bill says little about the next year's revenue.

  • Slow pharma spending decisions

    Large drugmakers still sign trials more slowly than they did before the recent policy and funding turmoil, which delays when new awards turn into revenue.

  • Flat margins on growing revenue

    Revenue growth is not reaching the bottom line, because pass-through costs carry no profit and acquired businesses dilute margins, leaving profitability roughly flat.

  • AI tools pressure analytics pricing

    Cheaper AI tools and large technology firms could erode prices for IQVIA's information and analytics products, a risk the company itself lists in its filings.

Bull and bear points

Growth & Execution

In short: Awards and backlog are rising across both segments, but bookings are lumpy and slow to convert into revenue.

Bull · 1

  • Net new bookings rose for a fourth straight quarter, up 13% year over year

    Growth in the trailing twelve-month award figure, rather than one quarter's ratio, indicates demand for outsourced trials is broadening across large, midsize and emerging biotech clients.

    Q2 FY2026 call
Bear · 2

  • Management now calls its own book-to-bill ratio a poor predictor

    IQVIA used to lead its quarterly summary with the bookings ratio; it now argues the figure cannot be compared across the industry and points clients to awards measured over twelve months.

    Tone shiftQ3 FY2025 → Q1 FY2026

  • Large drugmakers still commit to trials more slowly than before

    Management says sponsors remain deliberate about capital deployment after three to four years of policy disruption, and because awards burn over roughly five years, a slow signature today shows up in revenue much later.

    Q1 FY2026 call

Profitability & Financial Strength

In short: Cash flow is strong and buybacks continue, but margins stay flat as pass-throughs carry no profit.

Bull · 2

  • Free cash flow covers nearly all of adjusted net income

    Free cash flow of $2.2 billion over the last twelve months equals about 13% of revenue, which pays for the buyback and bolt-on acquisitions without relying on new borrowing.

    Filed financials

  • Productivity programs add about 90 basis points of margin

    Cost programs and early AI deployments added roughly 90 basis points of margin in the second quarter, which more than covered an 80-point drag from pass-through billing that carries no profit.

    Q2 FY2026 call
Bear · 1

  • Guidance holds EBITDA margin flat near 23% for 2026

    Revenue is guided up about 6.5% while adjusted EBITDA margin is held at roughly the prior year level, so higher sales are not translating into a higher share of profit.

    Q2 FY2026 call

Market Position

In short: IQVIA leads emerging biotech trials and holds unique health data, but pricing and data rules constrain it.

Bull · 2

  • Emerging biotech is 35% of clinical revenue and funding is rising

    Management says emerging biotech now accounts for about 70% of global trial starts and that IQVIA holds more revenue in that segment than any CRO peer, so a funding rebound reaches it before anyone else.

    Q2 FY2026 call

  • Partnership renewals expanded IQVIA's share with large pharma

    Top drugmakers reopened all their preferred clinical relationships during 2024 and 2025, and IQVIA says it widened both the number and scope of those deals while displacing incumbent providers.

    Q2 FY2026 call
Bear · 2

  • Repriced contracts and AI tools pressure analytics pricing

    IQVIA discounted some earlier awards to hold share, and its own annual report warns that wider use of AI and real-world evidence could reduce the perceived differentiation of its information and analytics offerings.

    10-K, filed 2026-02-17

  • Cross-border health data rules limit how patient data moves

    The information business depends on moving de-identified patient records between countries, and the legal mechanisms that permit it, such as registration under the EU framework, can be challenged or changed.

    10-K, filed 2026-02-17